Drug intelligence / Profile preview

FY001 + CART001

Development stage: Unknown
Lead developer: Fosun Pharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Antibody-Based Therapeutics
Administration: Intravenous

Overview

FY001 + CART001 is a combination therapy consisting of a switchable CAR-T cell therapy (CART001) and an antibody-based molecule (FY001). FY001 is designed to bind to CD20 on lymphoma cells. The activation of the CAR-T cells (CART001) occurs exclusively in the presence of FY001, enabling precise control over anti-tumor activity and potentially reducing off-tumor toxicity. This approach allows for fine-tuning of CAR-T cell activity in patients with refractory CD20-positive B-cell malignancies. The combination is being evaluated for safety and efficacy in clinical trials targeting relapsed or refractory CD20-positive B-cell lymphomas[3][10].

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on FY001 + CART001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FY001 + CART001.

Explore the full profile